155 related articles for article (PubMed ID: 24962948)
1. Infliximab for refractory oral ulcers.
Ryu HJ; Seo MR; Choi HJ; Baek HJ
Am J Otolaryngol; 2014; 35(5):664-8. PubMed ID: 24962948
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
Almoznino G; Ben-Chetrit E
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
[TBL] [Abstract][Full Text] [Related]
3. [Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].
Lestre S; Trindade F; Martins A; Baptista J; Feio AB; Lopes MJ
Acta Reumatol Port; 2009; 34(4):633-40. PubMed ID: 20852576
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease.
Lee JH; Jung JY; Bang D
J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111
[TBL] [Abstract][Full Text] [Related]
5. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.
Aikawa NE; Gonçalves C; Silva CA; Gonçalves C; Bonfá E; de Carvalho JF
Rheumatol Int; 2011 Aug; 31(8):1097-9. PubMed ID: 20012049
[TBL] [Abstract][Full Text] [Related]
6. Refractory Oral Ulcer Responsive to Infliximab: A Case Report.
Ito K; Shikata K; Haba K; Ito T
ORL J Otorhinolaryngol Relat Spec; 2019; 81(4):240-244. PubMed ID: 31256163
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival ulcers in Behçet's disease.
Zamir E; Bodaghi B; Tugal-Tutkun I; See RF; Charlotte F; Wang RC; Wechsler B; LeHoang P; Anteby I; Rao NA
Ophthalmology; 2003 Jun; 110(6):1137-41. PubMed ID: 12799237
[TBL] [Abstract][Full Text] [Related]
9. [Six cases with Behcet's disease presenting cervical ulcer].
Huang QS; Chen J; Hou XH; Wang LD; Liu Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):112-5. PubMed ID: 19570421
[TBL] [Abstract][Full Text] [Related]
10. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.
Li Y; Han Z; Wang X; Mo Z; Zhang W; Li A; Liu S
BMC Gastroenterol; 2013 Dec; 13():167. PubMed ID: 24321021
[TBL] [Abstract][Full Text] [Related]
12. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
15. Successful use of infliximab in a patient with neuro-Behçet's disease.
Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
[TBL] [Abstract][Full Text] [Related]
16. Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis.
Adler S; Baumgartner I; Villiger PM
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):607-11. PubMed ID: 22162223
[TBL] [Abstract][Full Text] [Related]
17. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment for severe orogenital ulceration in Behçet's disease.
Connolly M; Armstrong JS; Buckley DA
Br J Dermatol; 2005 Nov; 153(5):1073-5. PubMed ID: 16225632
[No Abstract] [Full Text] [Related]
19. Biologics in oral medicine: ulcerative disorders.
O'Neill ID; Scully C
Oral Dis; 2013 Jan; 19(1):37-45. PubMed ID: 22471882
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
